Translational Research in Melanoma

Surgical Oncology Clinics of North America

Volumn 17, Issue 2, 2008, Pages 391-419

  Tsai, Susan ^a   Sabel, Michael S ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 7 HYDROXYSTAUROSPORINE; ABERGRIN; BEVACIZUMAB; BORTEZOMIB; CANCER VACCINE; CARBOPLATIN; CEDIRANIB; CHIR 265; CILENGITIDE; CNTO 95; DACARBAZINE; EPIGALLOCATECHIN GALLATE; EVEROLIMUS; IMATINIB; INTERFERON; ISIS 3521; LENALIDOMIDE; M VAX; MARIMASTAT; MONOCLONAL ANTIBODY LM 609; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OBLIMERSEN; PACLITAXEL; PI 88; RESVERATROL; SEMAXANIB; SORAFENIB; SUNITINIB; TANESPIMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIANGIOGENIC THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER FUNCTION; LOW DRUG DOSE; LYMPHOCYTOPENIA; MEDICAL RESEARCH; MELANOMA; NONHUMAN; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTICARCINOGENIC AGENTS; ANTIGENS, CD; APOPTOSIS; CANCER VACCINES; DENDRITIC CELLS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; SIGNAL TRANSDUCTION; TISSUE THERAPY; VACCINES, SUBUNIT;

EID: 41049113485     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.12.003     Document Type: Review

References (171)

1. Gilchrest B.A., Eller M.S., Geller A.C., et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 340 (1999) 1341-1348
2. Meyskens F.L., Farmer P.J., and Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributible risk. Clin Cancer Res 10 (2004) 2581-2583
3. Albino A.P., Nanus D.M., Mentle I.R., et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 4 (1989) 1363-1374
4. Pollock P.M., Yu F., Qiu L., et al. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines. Oncogene 11 (1995) 663-668
5. Vink A.A., Moodycliffe A.M., Shreedhar V., et al. The inhibition of antigen-presenting activity of dendritic cells resulting from UV irradiation of murine skin is restored by in vitro photorepair of cyclobutane pyrimidine dimers. Proc Natl Acad Sci U S A 94 (1997) 5255-5260
6. Lao C.D., Demierre M.-F., and Sondak V.K. Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Rev Anticancer Ther 6 11 (2006) 1559-1568
7. Hawk E., and Viner J.L. The critical role of risk-benefit assessments in cancer prevention. Cancer Epidemiol Biomarkers Prev 14 (2005) 297-298
8. Noonan F.P., Dudek J., Merlino G., et al. Animal models of melanoma: an HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events. Pigment Cell Res 16 (2003) 16-25
9. Schatzkin A., and Gail M. The promise and peril of surrogate end points in cancer research. Nat Rev Cancer 2 1 (2002) 19-27
10. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the Novel Raf Kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 965-972
11. Raymond E., Alexandre J., Depenbrock H., et al. CCI-779, a rapamycin analog with antitumor activity: a phase I study utilizing a weekly schedule. [abstract]. Proc Am Soc Clin Oncol 19 (2000) 728
12. Margolin K., Longmate J., Baratta T., et al. CCI-779 in metastatic melanoma. Cancer 104 (2005) 1045-1048
13. Schmitt C.A., Rosenthal C.T., and Lowe S.W. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med 6 (2000) 1029-1035
14. Jansen B., Schlagbauer-Wadl H., Brown B.D., et al. bcl-2 antisence therapy chemosensitizes human melanoma in SCID mice. Nat Med 4 (1998) 232-234
15. Jansen B., Wacheck V., Heere-Rees E., et al. Chemosensitization of malignant melanoma BCL2 antisense therapy. Lancet 356 (2000) 1728-1733
16. Millward M.J., Bedikian A.Y., Conry R.M., et al. Randomized multination phase III trial of DTIC with or without Bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma. [abstract]. Proceedings of the American Society of Clinical Oncology 7505 (2004)
17. Amiri K.I., Horton L.W., LaFleur J.B., et al. Augmenting chemosensitivity of malignant melanoma tumors via proteosome inhibition: implication for bortezomib as a therapeutic agent for malignant melanoma. Cancer Res 63 (2005) 4912-4918
18. Markovic S.N., Geyer S.M., Dawkins F., et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103 12 (2005) 2584-2589
19. Yancopoulous G.D., Davis S., Gale N.W., et al. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
20. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, flourouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
21. Carson W.E., Biber J.E., Shah N., et al. A phase 2 trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma. [abstract 2873]. Proc Am Soc Clin Oncol 22 (2003)
22. Bartlett J.B., Dredge K., and Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nature Reviews 4 (2004) 314-322
23. Haslett P.A., Corral L.G., Albert M., et al. Thalidomide co-stimulates primary human T-lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8 + subset. J Exp Med 187 (1998) 1885-1892
24. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173 (1991) 699-703
25. Reirez A.B., Richter M.F., Fernandes S., et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res 14 (2004) 527-531
26. Hwu W.J., Lis E., Menell J.H., et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103 (2005) 2590-2597
27. Krown S.E., Niedzwiecki D., Hwu W.J., et al. Phase II study of temozolomide and thalidomide in patients with metastaticmelanoma in the brain: high rate of thromboembolic events. Cancer 107 (2006) 1883-1890
28. Gutheil J.C., Campbell T.N., Pierce P.R., et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monocolonal antibody to the intergrin aVb3. Clin Cancer Res 6 (2000) 3056-3061
29. Hersey P., Sosman J.A., O'Day S.J., et al. A phase II randomized open label study evaluating the empty tumor activity of MED-522, humanized monoclonal antibody directed against the human aVb3 integrin +/- DTIC in patients with metastatic melanoma. J Clin Oncol 23 (2005) 2707
30. Van Der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recongized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
31. Maeuer M.J., Storkus W.J., Kirkwood J.M., et al. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6 (1996) 11-24
32. *0201 binding residues. J Immunol 157 6 (1996) 2539-2548
33. Dyall R., Bowne W.B., Weber L.W., et al. Heteroclitic immunization induces tumor immunity. J Exp Med 188 9 (1998) 1553-1561
34. Chianese-Bullock K.A., Pressley J., Garbee C., et al. MAGE-A1, MAGE-A10 and gp100-derived peptides are immunogenic when combined with GM-CSF and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine. J Immunol 174 5 (2005) 3080-3086
35. Pullarkat V., Lee P.P., Scotland R., et al. A phase I trial of SD-9427 with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 9 4 (2003) 1301-1312
36. Weber J., Sondak V.K., Scotland R., et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97 1 (2003) 186-200
37. Lee P.P., Wang F., Kuniyoshi J., et al. Effects of Interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 19 (2001) 3836-3847
38. Slingluff C.L., Petroni G.R., Yamshchikov G.V., et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 22 22 (2004) 4474-4485
39. Atzpodien J., Fluck M., and Reitz M. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients. Cancer Biother Radiopharm 19 6 (2004) 758-763
40. Sanderson K., Scotland R., Lee P., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23 4 (2005) 741-750
41. Marchand M., Punt C.J., Aamdal S., et al. Immunization of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39 (2003) 70-77
42. Davis I.D., Chen W., Jackson H., et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad intergrated antibody and CD4 + and CD8 + T cell responses in humans. Proc Natl Acad Sci U S A 101 (2004) 10697-10702
43. Lindenmann J. Speculations on idiotypes of homobodies. Ann Immunol (Paris) 124 (1973) 171-184
44. Jerne N.K. Towards a network theory of the immune system. Ann Immunol (Paris) 125C (1974) 373-389
45. Chatterjee M.B., Baral N., Chatterjee S.K., et al. Counterpoint. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer Immunol Immunother 49 (2000) 133-141
46. Bhattacharya-Chatterjee M., and Kohler G. Anti-idiotype tumor vaccines. Adv Exp Med Biol 251 (1990) 113-128
47. Chatterjee M.B., Foon K.A., and Kohler H. Idiotypic antibody immunotherapy of cancer. Cancer Immunol Immunother 38 (1994) 75-82
48. Mittelman A., Wang X., Matsumoto K., et al. Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 14 (1995) 175-181
49. Saleh M.N., Stapleton J.D., Khazaeli M.B., et al. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunol 151 (1993) 3390-3398
50. Saleh M.N., Lalisan Jr. D.Y., Pride M.W., et al. Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease. J Immunother (1997) 21 5 (1998) 379-388
51. McCaffery M., Yao T.J., Williams L., et al. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res 2 (1996) 679-686
52. Foon K.A., Lutzky J., Baral N., et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 18 2 (2000) 376-384
53. Przepiorka D., and Srivastava P.K. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol Med Today 4 11 (1998) 478-484
54. Janetzki S., Blachere N.E., and Srivastava P.K. Generation of tumour specific cytotoxic T-lymphocytes and memory T-cells by immunization with tumor derived heat-shock proteins gp96. J Immunother 21 (1998) 269-276
55. Castellino F., Boucher P.E., Eichelberg K., et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 191 (2000) 1957-1964
56. Arnold D., Faath S., Rammensee H., et al. Cross priming of minor histocompatibility antigen-specific cytotoxic T-cells upon immunization with the heat shock protein gp96. J Exp Med 182 3 (1995) 885-889
57. Heikema A., Agsteribbe E., Wilschut J., et al. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol Lett 57 (1997) 69-74
58. Tamura Y., Peng P., Liu K., et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278 (1997) 117-120
59. Binder R.J., Blachere N.E., and Srivastava P.K. Heat shock protein chaperoned peptides but not free peptides introduced into the cytosol are presented effeciently by MHC I molecules. J Biol Chem 276 20 (2001) 17163-17171
60. Ma J.-H., Sui Y.-F., Ye J., et al. Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo. Cancer Immunol Immunother 54 (2005) 907-914
61. Rivoltini L., Castelli C., Carrabba M., et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T-cells. J Immunol 171 7 (2003) 3467-3474
62. Parmiania G. Phase II study of HSPCC-96 in combination with GM-CSF and IFN-a in stage IV malignant melanoma. Proceedings of the American Society of Clinical Oncology 22 14S (2004) 7510
63. Parmiani G., Rivoltini L., Belli F., et al. Vaccination of metastatic melanoma patients with the autologous heat-shock protein peptide complex-96 (HSPPC-96, Oncophage) which containes melanoma peptides, results in a specific T-cell response and clinical response. J Clin Oncol 20 20 (2002) 4169-4180
64. Rivoltini L., Castelli C., Squarcina P., et al. Heat shock protein gp96 presentation of antigenic peptides leads to in vitro sensitization and in vivo expansion of tumor-specific T cells. [abstract]. Proc Am Assoc Cancer Res (2002) 719
65. Parmiani G., Belli F., Testori A., et al. Vaccination with autologous heat-shock protein peptide complex-96 (HSPPC-96, Oncophage) in metastatic melanoma. [abstract]. Proc Am Assoc Cancer Res (2001) 799
66. Eton O., East M., Ross M.I., et al. Autologous tumor-derived heat-shock protein peptide complex-96 in patients with metastatic melanoma. [abstract]. Proc Am Assoc Cancer Res (2000) 3463
67. Antigenics Press Release. Available at: http://www.antigenics.com/news/2005/1010.phtml. Accessed February 5, 2008.
68. Mastrangelo M.J., Maguire Jr. H.C., Sato T., et al. Active specific immunization in the treatment of patients with melanoma. Semin Oncol 23 (1996) 773-781
69. Sun Y., Paschen A., and Schandorf D. Cell-based vaccination against melanoma- background, preliminary results and perspective. J Mol Med 77 8 (1999) 593-608
70. Berd D., Maguire Jr. H.C., McCue P., et al. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 8 11 (1990) 1858-1867
71. McIllmurray M.B., Embleton M.J., Reeves W.G., et al. Controlled trial of active immunotherapy in the management of stage IIB malignant melanoma. Br Med J 1 6060 (1977) 540-542
72. Aranha G.V., McKhann C.F., Grage T.B., et al. Adjuvant immunotherapy of malignant melanoma. Cancer 43 (1979) 1297-1303
73. Berd D., Maguire Jr. H.C., and Mastrangelo M.J. Treatment of human melanoma with a hapten modified autologous vaccine. Ann NY Acad Sci 690 (1993) 147-152
74. Berd D., Maguire Jr. H.C., Schuchter L.M., et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15 (1997) 2359-2370
75. Berd D., Kairys J., Dunton C., et al. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol 25 6 (1998) 646-653
76. Takahashi T., Johnson T.D., Nishinaka Y., et al. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol 112 2 (1999) 205-209
77. Morton D.L., Foshag L.J., Hoon D.S., et al. Prolongation of survival in metastatic melanoma after specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216 (1992) 463-482
78. Mitchell M.S., Harel W., Kan-Mitchell J., et al. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results and possible mechanisms of action. Ann N Y Acad Sci 690 (1993) 153-166
79. Mitchell M.S., and Von Eschen K.B. Phase III trial of Melacine melanoma vaccine versus combination chemotherapy in the treatment of stage IV melanoma. [abstract]. Proceedings of the American Society of Clinical Oncology 16 (1997) 1778
80. Mitchell M.S., Harel W., and Groshen S.G. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 10 (1992) 1158-1164
81. Sondak V.K., Liu P.Y., Tuthill R.J., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20 8 (2002) 2058-2066
82. Morton D.L., and Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 46 (1996) 225-244
83. Chan A.D., and Morton D.L. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 25 (1998) 611-622
84. Morton D.L. Cytoreductive surgery and adjuvant immunotherapy in the management of metastatic melanoma. Tumori 87 4 (2001) S57-S59
85. Hsueh E.C., Nizze A., Essner R., et al. Adjuvant immunotherayp with a polyvalent melanoma cell vaccine (PMCV) prolongs survival after complete resection of distant melanoma metastases. [abstract]. Proceedings of the American Society of Clinical Oncology 16 (1997) 492
86. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
87. Dhodapkar M.V., Steinman R.M., Sapp M., et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104 (1999) 173-180
88. Trefzer U., Herberth G., Wohlan K., et al. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical effects. Vaccine 23 (2005) 2367-2373
89. Dillman R., Selvan S., Schiltz P., et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells and GM-CSF: planned interim analysis. Cancer Biotherapy & Radiopharmaceuticals 19 5 (2004) 658-665
90. Sabel M.S., Hess S.D., Egilmez N.K., et al. CTLA-4 blockade augments human T lymphocyte mediated suppression of lung tumor xenografts in SCID mice. Cancer Immunol Immunother 54 (2005) 944-952
91. Attia P., Phan G.Q., Maker A.V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA-4. J Clin Oncol 23 (2005) 6043-6053
92. Ribas A., Camacho L.H., Lopez-Berestein G., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-CTLA-4 monoclonal antibody CP-675206. J Clin Oncol 23 (2005) 8968-8977
93. Irie R.F., Matsuki T., and Morton D.L. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1 (1989) 786-787
94. Irie R.F., and Morton D.L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci U S A 83 (1986) 8694-8698
95. Grimm E.A., Robb R.J., Roth J.A., et al. Lymphokine-activated killer cell phenomenon, III: evidence that IL-2 is sufficient for direct activation of peripheral blood into lymphokine-activated killer cells. J Exp Med 158 (1983) 1356-1361
96. Rosenberg S.A., Lotze M.T., Topalian S.L., et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjuction with lymphokine activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85 (1993) 622-632
97. Rivoltini L., Carabba M., Huber V., et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 188 (2002) 97-113
98. Topalian S.L., Solomon D., and Rosenberg S.A. Tumor specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142 (1989) 3714-3725
99. Rosenberg S.A., Yannelli J.R., Yang J.C., et al. Treatment of patients wtih metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 86 (1994) 1159-1166
100. Ridolfi L., Ridolfi R., Riccobon A., et al. Adjuvant immunotherayp with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma. J Immunother 26 (2003) 156-162
101. Li Q., and Chang A.E. Adoptive T-cell immunotherapy of cancer. Cytokines Cell Mol Ther 5 (1999) 105-117
102. Speiser D.E., and Romero P. Toward improved immunocompetence of adoptively transferred CD8 + T cells. J Clin Invest 115 6 (2005) 1467-1469
103. Rosenberg S.A., and Dudley M.E. Cancer regression in patietns with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A 101 Suppl 2 (2004) 14639-14645
104. Labarriere N., Pandolfino M.C., Gervois N., et al. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 51 (2002) 532-538
105. Dreno B., Nguyen J.M., Khammari A., et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 51 (2002) 539-546
106. Meijer S.L., Dois A., Urba W.J., et al. Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene modified autologous tumor cells. J Immunother 25 4 (2002) 359-372
107. Geiger J.D., Wagner P., Shu S., et al. A novel role for autologous tumor cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg Oncol 1 (1992) 199-208
108. Geiger J.D., Wagner P., Cameron M., et al. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother 13 (1993) 153-165
109. Winter H., Hu H.-M., Poehlein C.H., et al. Tumour-induced polarization of tumor vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer study. Immunology 108 (2003) 409-419
110. Chang A.E., Aruga A., Cameron M.J., et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15 (1997) 796-807
111. Chang A.E., Yoshizawa H., Sakai K., et al. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 53 (1993) 1043-1050
112. Chang A.E., Li Q., Jiang G., et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2, in Stage IV renal cell cancer. J Clin Oncol 21 5 (2003) 884-890
113. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006) 126-129
114. Mitchell M.S., Abrams J., Thompson J.A., et al. Randomized trial of an allogeneic melanoma lysate vaccine with low dose interferon alfa-2b compared with high dose interferon alfa 2b for resected stage III cutaneous melanoma. J Clin Oncol 25 15 (2007) 2078-2085
115. Morton D.L., Mozzillo N., Thompson J.F., et al. An international, randomized, double-blind, phase 3 study of the specific active immunotherapy agent, Onamelatucel-L (Canvaxin), compared to placebo as a post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol 13 Suppl 5 (2006) 5
116. Richards J.M., Testori A., Whitman E., et al. Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma. Proceedings of the American Society of Clinical Oncology 24 Suppl 18 (2006) 8002
117. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 9 (2001) 2370-2380
118. Wallack M.K., Sivanandham M., Balch C.M., et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncosylate-active specific immunotherapy for patients with stage II melanoma. Cancer 75 1 (1995) 34-42
119. Hersey P., Coates A.S., McCarthy W.H., et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 20 20 (2002) 4181-4190
120. Voit C., Kron M., Schwurzer-Voit M., et al. Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease. J Dtsch Dermatol Ges 1 (2003) 120-125
121. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4 (1998) 321-327
122. Cormier J.N., Salgaller M.L., Prevette T., et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan-A. Cancer J Sci Am 3 (1997) 37-44
123. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 163 (1999) 1690-1695
124. Powell D.J., and Rosenberg S.A. Phenotypic and functional maturation of tumor antigen-reactive CD8 + T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother 27 1 (2004) 36-47
125. Speiser D.E., Lienard D., Rufer N., et al. Rapid and strong human CD8 + T cell responses to vaccination with peptide, IFA and CpG oligodeoxynucleotide 7909. J Clin Invest 115 3 (2005) 739-746
126. Wang F., Bade E., Kuniyoshi J., et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 5 (1999) 2756-2765
127. Marchand M., Van Baren N., Weynants P., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-1. Int J Cancer 80 (1999) 219-230
128. Scheibenbogen C., Schmittel A., Keilholz U., et al. Phase II trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony stimulating factor in patients with metastatic melanoma. J Immunother 23 (2000) 275-281
129. Jager E., Gnjatic S., Nagata Y., et al. Induction of primary NY-ESO-1 immunity; CD8 + T lymphocyte and antibody response in peptide-vaccinated patients with NY-ESO-1 + cancers. Proc Natl Acad Sci U S A 97 (2000) 12198-12203
130. *04 patients wtih metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 27 6 (2004) 472-477
131. Phan G.Q., Yang J.C., Sherry R.M., et al. Cytotoxic regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patietns wtih metastatic melanoma. Proc Natl Acad Sci U S A 100 14 (2003) 8372-8377
132. Guthman M.D., Bitton R.J., Carnero A.J., et al. Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother 27 6 (2004) 442-451
133. Livingston P.O., Wong G.Y., Adluri S., et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12 5 (1994) 1036-1044
134. Chapman B.P., Morissey D.M., Panageas K.S., et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-KLH + QS21 vaccine: a dose-response study. Clin Cancer Res 6 (2000) 874-879
135. Belli F., Arienti F., Sule-Soso J., et al. Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol Immunother 44 (1997) 197-203
136. Maio M., Fonsatti E., Lamaj E., et al. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 51 1 (2002) 9-14
137. Das Gupta T.K., Cohen E.P., and Richards J.M. Phase I evaluation of interleukin-2 transfected irradiated allogeneic melanoma for the treatment of metastatic melanoma. Hum Gene Ther 8 14 (1997) 1701-1714
138. Hsueh E.C., Gupta R.K., Qi K., et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16 (1998) 2913-2920
139. Morton D.L., Hsueh E.C., Essner R., et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resecton of melanoma metastatic to regional lymph nodes. Ann Surg 236 4 (2002) 438-449
140. Cassel W.A., Murray D.R., and Phillips H.S. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncosylate. Cancer 52 (1983) 856-860
141. Wallack M.K., McNally K.R., Leftheriotis E., et al. A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncosylates. Cancer 57 3 (1986) 649-655
142. Hersey P. Active immunotherapy with viral lysates of micrometastases following surgical removal of high risk melanoma. World J Surg 16 (1992) 251-260
143. Mahvi D.M., Shi F.S., Yang N.S., et al. Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study. Hum Gene Ther 13 14 (2002) 1711-1721
144. Kosomoto M., Umeda S., Ikubo A., et al. Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother 50 7 (2001) 373-381
145. Stingl G., Brocker E.B., Mertelsmann R., et al. Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. J Mol Med 75 4 (1997) 297-299
146. Moiseyenko V.M., Danilov A.O., Baldueva I.A., et al. Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors. Ann Oncol 16 1 (2005) 162-168
147. Soiffer R., Lynch T., Mihm M.F., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor generates potent anti-tumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 85 (1998) 13141-13146
148. Schreiber S., Kampgen E., Wagner E., et al. Immunothearpy of metastatic melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gene Ther 10 6 (1999) 983-993
149. Moller P., Sun Y., Dorbic T., et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer 77 (1998) 1907-1916
150. Sun Y., Jurgovsky K., Moller P., et al. Vaccination with IL-12 gene modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5 (1998) 481-490
151. Abdel-Wahab Z., Weltz C., Hester D., et al. A phase I clinical trial of immunotherapy with interferon-gamma gene modified autologous melanoma cells: monitoring the humoral immune response. Cancer 80 (1997) 401-412
152. Veelken H., Mackensen A., Lahn M., et al. A phase I clinical study of autologous tumor cells plus interleukin-2 gene transfected allgeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 6 (1997) 269-277
153. Nawrocki S., Murawa P., Malicki J., et al. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett 74 (2000) 81-86
154. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 3 (1998) 328-332
155. Panelli M.C., Wunderlich J., Jeffries J., et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 23 (2000) 487-498
156. Mackensen A., Herbst B., Chen J.L., et al. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34 (+) hematopoietic progenitor cells. Int J Cancer 86 3 (2000) 385-392
157. Toungouz M., Libin M., Bulte F., et al. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with MAGE-A1/A3 positive tumors. J Leukoc Biol 69 (2001) 937-943
158. Gajewski G.F., Fallarino F., Ashikari A., et al. Immunization of HLA-A2 + melanoma patients wtih MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin-12. Clin Cancer Res 7 (2001) 895s-901s
159. Thurner B., Haendle I., Roder C., et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190 11 (1999) 1669-1678
160. Godelaine D., Carrasco J., Lucas S., et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171 9 (2003) 4893-4897
161. Schuler-Thurner B., Dieckmann D., Keikavoussi P., et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1 + melanoma patietns by mature monocyte derived dendritic cells. J Immunol 165 (2000) 3492-3496
162. Banchereau J., Palucka A.K., Dhodapkar M.V., et al. Immune and clinical responses in patients with metastatic melanoma to CD34 + progenitor-derived dendritic cell vaccine. Cancer Res 61 (2001) 6451-6458
163. Lau R., Wang F., Jeffery G.G., et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24 (2001) 66-78
164. Hersey P., Menzies S.W., Halliday G.M., et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 53 2 (2004) 125-134
165. Lotze M.T., Shurin M., Esche C., et al. Interleukin-2 developing additional cytokine gene therapy using fibroblasts or dendritic cells to enhance tumor immunity. Cancer J Sci Am 6 (2000) S61-S66
166. de Vries I.J., Bernsen M.R., Lesterhuis W.J., et al. Immunomonitoring tumor-specfic T-cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23 24 (2005) 5779-5787
167. Butterfield L.H., Ribas A., Dissette V.B., et al. Determinant spreading associated with clinical response in dendritic cell-based immunohterapy for malignant melanoma. Clin Cancer Res 9 (2003) 998-1008
168. Ribas A., Glaspy J.A., Lee Y., et al. Role of dendritic cell phoenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27 5 (2004) 354-367
169. Chakraborty N.G., Sporn J.R., Tortora A.F., et al. Immunization with a tumor-cell-lysate loaded autologous-antigen presenting cell based vaccine in melanoma. Cancer Immunol Immunother 47 (1998) 58-64
170. Chang A.E., Redman B.G., Whitfield J.R., et al. A phase I trial of tumor lysate pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 8 (2002) 1021-1032
171. Griffioen M., Borghi M., Schrier P.I., et al. Analysis of T-cell responses in metastatic mealnoma patients vaccinated with dendritic cells pulsed with tumor lysates. Cancer Immunol Immunother 3 (2004) 715-722